Title : The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

Pub. Date : 2020 Sep

PMID : 32645640






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced treatment interval. Cladribine keratin 20 Homo sapiens